Desenvolvimento e avaliação de formulação sólida oral obtida por impressão 3D contendo alopurinol

Abstract

Canine leishmaniasis is a disease of great significance in endemic areas, affecting the health of dogs and posing a zoonotic risk. The treatment of the disease often involves the use of allopurinol, with the dosage adjusted based on the dogs' body weight (10 mg/kg). However, the commercially available formulations are designed for human use and come in limited dosages (100 mg or 300 mg), requiring dose adjustments, usually by tablet splitting, which may compromise dosing accuracy. 3D printing emerges as an innovative solution, enabling the production of customized pharmaceutical forms with greater precision and flexibility. The semi-solid extrusion technique, performed at room temperature, facilitates drug incorporation and ensures high-quality tablets with reduced thermal degradation risk. Studies involving physicochemical characterization, solubility, and dissolution profile are essential. The use of 3D printing to produce personalized allopurinol dosage forms represents a significant advancement in the treatment of canine leishmaniasis, offering a safer and more effective approach.